Jazz Pharmaceuticals (NASDAQ:JAZZ) Posts Quarterly Earnings Results, Beats Estimates By $1.67 EPS

Jazz Pharmaceuticals (NASDAQ:JAZZ) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $6.34 EPS for the quarter, beating analysts’ consensus estimates of $4.67 by $1.67, FiscalAI reports. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The firm’s revenue for the quarter was up 19.1% on a year-over-year basis. During the same quarter last year, the company posted $1.68 earnings per share.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

• Record Q1 results — total revenue of $1.07B (+19% YoY), non-GAAP adjusted EPS of $6.34 and $408M cash from operations, and management reaffirmed full?year revenue guidance of $4.25–4.5B.
• Ziihera (zanidatamab) sBLA accepted under Real?Time Oncology Review with priority review and a PDUFA date of August 25, 2026; company highlights HERIZON?GEA?01 data (triplet median OS 26.4 months) and plans to launch immediately on approval.
• Broad commercial momentum — XYWAV $408M (18% growth, ~16,600 active patients), Epidiolex $250M (15% growth, 16% volume growth), Zepzelca $101M (60% growth) and Modeyso $41M with ~500 patients treated and a stated ~$500M peak potential.
• Multiple upcoming clinical catalysts that could drive value — mid?year second interim OS readout for zanidatamab in GEA, ACTION (Modeyso) topline expected late?2026/early?2027, and EmpowHER (breast cancer) enrollment on track for top?line in late?2027/early?2028.
• Management cautions on second?half headwinds — anticipated growth of high?sodium oxybate generics and possible new wake?promoting entrants (and declining XYREM/authorized generic sales) could pressure the oxybate franchise, and Zepzelca second?line use is expected to decline.

Jazz Pharmaceuticals Stock Up 2.0%

Jazz Pharmaceuticals stock traded up $4.20 during trading hours on Tuesday, hitting $212.26. 1,214,968 shares of the stock traded hands, compared to its average volume of 920,288. The firm’s 50-day moving average price is $190.45 and its two-hundred day moving average price is $171.65. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. The company has a market cap of $13.32 billion, a PE ratio of -35.55, a PEG ratio of 0.36 and a beta of 0.27. Jazz Pharmaceuticals has a one year low of $97.50 and a one year high of $212.57.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Norbert G. Riedel sold 3,415 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $192.00, for a total transaction of $655,680.00. Following the sale, the director directly owned 7,024 shares in the company, valued at $1,348,608. The trade was a 32.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Neena M. Patil sold 55,600 shares of the company’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the sale, the executive vice president directly owned 56,862 shares in the company, valued at approximately $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 74,015 shares of company stock worth $14,180,486. 4.30% of the stock is owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in JAZZ. Amundi bought a new stake in Jazz Pharmaceuticals in the fourth quarter worth $372,000. Syon Capital LLC purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth about $290,000. CIBC Bancorp USA Inc. purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth about $273,000. Brooklyn Investment Group raised its position in shares of Jazz Pharmaceuticals by 144.7% in the 3rd quarter. Brooklyn Investment Group now owns 1,950 shares of the specialty pharmaceutical company’s stock worth $257,000 after purchasing an additional 1,153 shares during the last quarter. Finally, Commerce Bank purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth about $242,000. 89.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Morgan Stanley upped their price objective on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Bank of America raised their target price on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Wells Fargo & Company upped their price target on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Barclays increased their price objective on Jazz Pharmaceuticals from $224.00 to $225.00 and gave the stock an “overweight” rating in a report on Monday, April 20th. Finally, Leerink Partners boosted their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $216.87.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.